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untington’s disease (HD) is a neurodegenerative
disorder caused by an expanded polyglutamine
(polyQ) tract in the huntingtin (htt) protein. Mutant
htt toxicity is exposed after htt cleavage by caspases and
other proteases release NH
 
2
 
-terminal fragments contain-
ing the polyQ expansion. Here, we show htt interacts and
colocalizes with cdk5 in cellular membrane fractions.
Cdk5 phosphorylates htt at Ser434, and this phosphory-
lation reduces caspase-mediated htt cleavage at residue
513. Reduced mutant htt cleavage resulting from cdk5
H
 
phosphorylation attenuated aggregate formation and
toxicity in cells expressing the NH
 
2
 
-terminal 588 amino
acids (htt588) of mutant htt. Cdk5 activity is reduced in
the brains of HD transgenic mice compared with controls.
This result can be accounted for by the polyQ-expanded
htt fragments reducing the interaction between cdk5 and
its activator p35. These data predict that the ability of
cdk5 phosphorylation to protect against htt cleavage,
aggregation, and toxicity is compromised in cells ex-
pressing toxic fragments of htt.
 
Introduction
 
Huntington’s disease (HD) is an autosomal dominant progres-
sive neurodegenerative disorder characterized by abnormal
movements, emotional disturbances, and cognitive decline
(Rubinsztein and Carmichael, 2003). HD is caused by an ex-
panded CAG trinucleotide repeat tract close to the 5
 
 
 
 end of the
coding region of the HD gene, which is translated into an abnor-
mally long polyglutamine (polyQ) stretch in the huntingtin (htt)
protein. HD is associated with uninterrupted polyQ tracts of 38
or more residues. Genetic and transgenic data suggest that the
mutation causes disease predominantly by gain-of-function
mechanisms. HD pathology is characterized by intraneuronal
aggregates in both the nucleus and in neuronal processes. Exon
1 fragments of htt with expanded polyQ repeats are sufficient to
cause cell death in cell models or disease in animal models, and
such short fragments show greater toxicity and aggregation
compared with full-length mutant constructs (Goldberg et al.,
1996; Wellington et al., 2000). Htt can be cleaved by caspases,
calpains, and aspartic proteases to form short NH
 
2
 
-terminal
toxic fragments with the expanded polyQ repeats in vitro and in
HD brains (Wellington et al., 2000; Kim et al., 2001; Lunkes et
al., 2002). Thus, mutant htt cleavage resulting in toxic fragment
production may be an important rate-limiting step in HD patho-
genesis. However, the regulation of these events is poorly un-
derstood and no previous studies have identified factors other
than the proteases themselves that directly influence cleavage.
More than 20 htt-interacting proteins have been reported
(Harjes and Wanker, 2003). Htt is a predominantly cytoplasmic
protein (DiFiglia et al., 1995; Sharp et al., 1995) enriched in
membrane fractions (Gutekunst et al., 1995) and associated
with microtubules (Hoffner et al., 2002). Htt may have roles in
neurotransmission (Glynn et al., 2003), axonal transport, and
neuronal positioning (White et al., 1997). We were struck that
these functions have also been attributed to another membrane
and microtubule-associated protein, cdk5, a member of the
small serine/threonine Cdk family. Despite its biochemical and
sequence similarities with cdc2 (Meyerson et al., 1992), a role
for cdk5 in cell cycle regulation has not yet been identified
(Dhavan and Tsai, 2001). Cdk5 phosphorylates more than two
dozen proteins with diverse functions (Ino et al., 1994; Dhavan
and Tsai, 2001). Although cdk5 is expressed in widespread
adult tissues, its activity is highest in neurons because the cdk5-
activating proteins p35/p39 are highly expressed in these cells
(Tsai et al., 1993; Tang et al., 1995). Both htt and cdk5 are ex-
pressed ubiquitously with highest levels in neurons of the CNS,
and htt or cdk5 knockout mice show overlapping phenotypes—
neuronal cell death and embryonic or perinatal lethality (Zeitlin
et al., 1995; Ohshima et al., 1999).
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Results
 
Htt interacts with cdk5
 
The overlapping subcellular localizations and functions of
htt and cdk5 and the presence of multiple minimum cdk5
phosphorylation sites within htt led us to test if these pro-
teins interact. Residues 1–588 of htt (htt588) pull down cdk5
(Fig. 1 A) in COS-7 cells. In the middle panel of Fig. 1 A,
cleavage products of htt588 are seen, which likely corre-
spond to htt552 and htt513 (Wellington et al., 2000). Us-
ing the same coimmunoprecipitation approach, we showed
that httwt588 (aa 1–588 of wild-type htt with 17 gluta-
mines-17Q), wtFLhtt (wild-type, full-length htt with 17Q),
httmu588 (aa 1–588 of mutant htt with 138Q), and muFLhtt
(mutant full-length htt with 138Q) all bound cdk5 (Fig. 1 B).
To narrow down the cdk5-binding region of htt, we ex-
pressed GST fused to amino acids 5–56 of htt (GST-htt5-56)
in 
 
Escherichia coli
 
, pulled down the recombinant protein
with glutathione-sepharose, and incubated it with cdk5-
transfected COS-7 cell lysate. Fig. 1 C shows that residues
5–56 of htt bind cdk5. We confirmed the physical interaction
of htt and cdk5 in neuronal cells by immunoprecipitating en-
dogenous htt in mouse brain lysate with anti-htt and demon-
strating that cdk5 was also pulled down with htt (Fig. 1 D, i).
Fig. 1 D (ii) shows the reverse experiment and confirms that
endogenous htt can also be immunoprecipitated by anti-
cdk5. We could not detect any binding between the cdk5 ac-
tivator, p35, and htt (unpublished data). These data reveal a
selective physical interaction between htt and cdk5.
 
Htt associates with cdk5 in membrane 
fraction
 
Htt is enriched in membrane fractions (Gutekunst et al., 1995).
To further investigate if htt and cdk5 interact significantly, we
tested if overexpression of htt led to an enrichment of cdk5 in
light membranes (LM) such as endosomes and ER vesicles.
Cdk5/empty vector or cdk5/htt551 were transfected to COS-7
cells. Fig. 2 A shows similar total cdk5 levels in both cdk5-
transfected cells and cdk5/htt-transfected cells (actin, enriched
in LM, was used as a protein loading control for total and LM
lysates). However, cdk5 levels in LM were much higher in
cells where cdk5 (rather than empty vector) was cotransfected
with htt. We tested the converse prediction that immunodeple-
tion of htt would reduce cdk5 levels in LM using endogenous
htt and cdk5 in mouse brain lysates. In both cytosolic and par-
ticularly in LM fractions, cdk5 levels were reduced after htt im-
munodepletion with anti-htt (181-500 aa; as a function of actin
levels; Fig. 2 B). Thus, the reduction of the cdk5 level is a spe-
cific consequence of htt immunodepletion, further confirming
the interaction between htt and cdk5 in LM. In neuronally dif-
ferentiated rat pheochromocytoma cells (PC-12 cells), we con-
firmed colocalization of endogenous htt and cdk5 (Fig. 2 C).
 
Cdk5 phosphorylates htt in vitro and 
in vivo
 
The htt–cdk5 interaction suggested that we should test if htt
was a cdk5 substrate. Six minimal cdk5 phosphorylation sites,
comprising Ser-Pro or Thr-Pro, were found within htt588.
GST-htt588 (but not the control protein, GST) is readily phos-
Figure 1. Htt interacts with Cdk5. (A) COS-7
cells were cotransfected with empty vector
and cdk5 (lanes 1–3) or Flag-tagged htt1-
588 (htt588) and cdk5 (lane 4). In all experi-
ments, empty vector controls have been per-
formed where appropriate and the amount of
empty vector DNA was equivalent to the
amount of experimental DNA (in this case,
htt588). Cell lysates were immunoprecipitated
with anti-Flag. Anti-Flag immunoprecipitates
were subjected to immunoblotting with anti-
cdk5 (top) or anti-Flag (middle). Total lysates
were immunoblotted with anti-cdk5 (bottom).
(B) COS-7 cells were cotransfected with
empty vector and cdk5 (lane 1); Flag-tagged,
wild-type, full-length htt (wtFLhtt) and cdk5
(lane 2); Flag-tagged, wild-type htt588
(httwt588) and cdk5 (lane 3); Flag-tagged,
mutant, full-length htt (muFLhtt) and cdk5
(lane 4); and Flag-tagged, mutant htt588
(httmu588) and cdk5 (lane 5), respectively.
Cell lysates were immunoprecipitated with
anti-Flag and immunoblotted with anti-cdk5
(top) and anti-Flag (middle), respectively. Total
lysates were immunoblotted with anti-cdk5
(bottom). (C) Bacterially expressed GST (lane 2)
and GST-htt (5–56 aa; lane 3) were incu-
bated with cdk5-transfected COS-7 cell lysate.
The cdk5 that associated with GST-htt (5–56
aa) was detected with anti-cdk5. The input signal represents 5% cdk5 in the total cell lysate (lane 1). (D, i) Mouse brain lysate was immunoprecipitated
with anti-Flag as a control (NS; lane 1) or anti-htt (181–800; lane 2). Cdk5 associated with htt as shown with anti-cdk5 antibody probing of Western
blot of immunoprecipitate (top). (ii) Mouse brain lysate was immunoprecipitated with anti-Myc as a control (NS; lane 1) or anti-cdk5 (C8; lane 2).
Htt associated with cdk5 as shown with anti-htt antibody probing of Western blot of immunoprecipitate (top). 
CDK5 PHOSPHORYLATES HUNTINGTIN • LUO ET AL.
 
649
 
phorylated by recombinant p35–cdk5 complex in vitro. (Fig.
3 A). Next, we immunoprecipitated p35–cdk5 complexes from
transfected COS-7 cells and incubated these complexes with
either httwt588 or httmu588 immunoprecipitated from COS-7
cells. In vitro phosphorylation assays showed that p35–cdk5
could phosphorylate both httwt588 and httmu588 to similar
extents (Fig. 3 B). In PC-12 cells, cdk5 activity dramatically
increases after NGF differentiation (Harada et al., 2001). To
test if htt is phosphorylated by cdk5 in vivo, we differentiated
PC-12 cells with NGF and treated cells with the cdk5 inhibitor
roscovitine or DMSO, and then pulled down the endogenous
htt with anti-htt. Serine phosphorylation of htt was assessed
with the antiphosphoserine antibody 16B4. As Fig. 3 C shows,
htt phosphorylation can be detected after differentiation but
was abolished with roscovitine (which inhibits cdk5). In vitro
kinase assays using histone H1 as a substrate were used to con-
firm that roscovitine is a potent inhibitor of cdk5 under these
conditions (Fig. 3 C).
Figure 2. Htt associates with cdk5 at LM. (A) Cdk5 was
cotransfected with empty vector/cdk5 (2:1) or Flag-htt1-551
(htt551)/cdk5 (2:1) in COS-7 cells. After 24 h, transfected
cells were harvested. Light membranes (LM) (including endo-
somes and all ER vesicles) were isolated. Total cellular (lanes
1 and 2) and LM (lanes 3 and 4) lysates were resolved by
SDS-PAGE and transferred to PVDF membrane, and then
probed with anti-cdk5 (top), anti-Flag (middle), and anti-actin
(bottom). The blots were quantified with ChemiImager. The
ratios of cdk5/actin in total lysates are set as 1. The relative
values of cdk5/actin in LM are shown. Three independent
experiments were performed. Error bars are SD; *, P   0.01.
(B) Mouse brain lysate was immunodepleted with anti-Flag
for control (lane 1) or anti-htt (lane 2). The lysate was separated
as cytosolic and LM fractions. Cytosolic and LM fractions
were resolved by 10% SDS-PAGE and transferred to PVDF
membranes. Anti-cdk5 (top), anti-htt (middle), and anti-actin
(bottom) were probed for cdk5, htt, and actin, respectively.
(C) PC-12 cells were induced to differentiate with 100 ng/ml
NGF for 3 d. Confocal immunofluorescence of PC-12 cells:
green, anti-htt, Alexa 488; red, anti-cdk5, Alexa 594;
blue, nuclei.
Figure 3. Cdk5 phosphorylates htt in vitro
and in vivo. (A) GST and GST-tagged htt1-588
(GST-htt588) (wild-type) were purified from E.
coli. Both proteins were phosphorylated by
0.1  g of p35–cdk5 complexes. Top panel
shows phosphorylated GST (lane 1) and GST-
htt588 (lane 2). Bottom panel shows purified
GST (lane 1) and GST-htt588 (lane 2). (B)
p35–cdk5 was cotransfected to COS-7 cells.
We immunoprecipitated p35–cdk5 with anti-
cdk5. Httwt588 or httmu588 were pulled
down with anti-Flag from distinct COS-7 cells
transfected with these constructs. The figure
shows in vitro kinase assays (top) and anti-
Flag blot (bottom) from p35–cdk5 incubated
with httwt588 and  -[
32P]ATP (lane 1) and
p35–cdk5 incubated with httmu588 and
 -[
32P]ATP (lane 2). The mixtures were re-
solved with 10% SDS-PAGE, and then trans-
ferred to PVDF membrane and subjected to
autoradiography (top). The PVDF membrane
was blotted with anti-Flag (bottom). (C) PC-12 cells were starved for 24 h, and then induced to differentiate with 100 ng/ml NGF for 48 h. Cells were
treated with 20  M of the cdk5 inhibitor roscovitine (Rosco) or DMSO (control) when cells were induced to differentiate with NGF. After 48 h of treatment,
PC-12 cells were lysed in buffer A containing phosphatase inhibitors. Htt was immunoprecipitated with anti-htt antibody, 2166, and then detected
with the antiphosphoserine antibody 16B4 (top) and anti-htt (middle). p35–cdk5 complex was pulled down from the differentiated PC-12 cells and an in
vitro kinase assay was performed in the presence of DMSO (lane 1) or roscovitine (lane 2) using histone H1 as a substrate (bottom). 
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Cdk5 phosphorylates htt at Ser 434 in 
vitro and in vivo
 
We mapped the cdk5 phosphorylation site(s) by first testing
p35–cdk5 phosphorylation of different truncated htt fragments
in vitro. Fig. 4 A (i) suggests the phosphorylation site(s) may be
between aa 551 and 415, as phosphorylation was observed with
htt551 but not with htt415 or htt314. We mutagenized the po-
tential cdk5 phosphorylation sites within this region. When Ser
434 (S434) was mutated to Ala, cdk5 failed to phosphorylate
htt588 in vitro (Fig. 4 A, ii), suggesting that S434 is the only
cdk5 phosphorylation site in htt588. We then tested if htt S434
was phosphorylated in vivo. Htt551/empty vector, htt551/p35,
and htt551 S434A/p35 were cotransfected into HeLa cells,
which express cdk5 but not the activators like p35/p39. After
 
32
 
P metabolic labeling, htt551 was phosphorylated only in the
presence of p35 (a cdk5-specific activator), confirming the
specificity of the reaction to cdk5 kinase activity. Consistent
with this specificity, the phosphorylation of htt was inhibited by
roscovitine. Mutation of htt S434 to A also prevented phos-
phorylation in vivo, which is consistent with our in vitro data
suggesting that this was the phosphorylation site in vivo (Fig. 4
B). This consensus cdk5 phosphorylation site is conserved in
htt orthologues across many vertebrates (Fig. 4 C).
To further confirm that htt is phosphorylated by cdk5 in
vivo, we developed an anti–htt-pS434 antibody (anti-pS434;
see Materials and methods). To test the antibody, we first phos-
phorylated either GST or GST-htt588 using p35–cdk5 complex
in vitro, and then probed gels of the reaction products with anti-
pS434. Anti-pS434 detected phospho–GST-htt588 (rather than
GST) that had an electrophoretic mobility similar to the GST-
htt588; comparable amounts of GST and GST-htt588 were
confirmed by anti-GST probing (Fig. 4 D). As htt can be phos-
phorylated at S434 in HeLa cells in the presence of cdk5 activity
(Fig. 4 B), we tested S434 phosphorylation in HeLa cells using
the anti-pS434 antibody. When htt551 or htt551 S434A were
cotransfected with either empty vector or p35 into HeLa cells,
anti-pS434 only detected htt phosphorylation when cdk5 was
activated (in the presence of p35) and required S at residue 434,
consistent with Fig. 4 B (Fig. 4 E). Fig. 4 F shows that mutant
polyQ-expanded htt551 (muhtt551) was phosphorylated at
S434 in HeLa cells in the presence of, but not the absence of,
p35. Thus, anti-pS434 recognizes phosphorylated htt and only
recognizes the specific band when htt is phosphorylated at resi-
due 434. To further show that htt is phosphorylated by cdk5 in
vivo, we first transfected PC-12 cells with empty vector (Fig. 4
G, lane 1), cdk5 (Fig. 4 G, lane 2), and cdk5 dominant-negative
form (cdk5DN; Fig. 4 G, lane 3) or treated with the cdk5 inhib-
itor roscovitine (Fig. 4 G, lane 4). The cells were then starved
for 24 h and induced with NGF, and transfected cells were
sorted with FACS. In cdk5-transfected cells, phosphorylation
of endogenous full-length htt slightly increased, but in cdk5DN
transfected cells, the phosphorylation is markedly reduced
Figure 4. Cdk5 phosphorylates htt at Ser434
in vitro and in vivo. (A, i) htt1-551 (htt551),
htt1-415 (htt415), and htt1-314 (htt314) were
immunoprecipitated with anti-Flag from COS-7
cells, and then  -[
32P]ATP and 0.1  g of re-
combinant p35–cdk5 complexes were added
to htt551 (lane 1), htt415 (lane 2), and htt314
(lane 3) to phosphorylate these htt variants.
The mixtures were subjected to SDS-PAGE and
transferred to PVDF membrane, subjected to
autoradiography (top), and blotted with anti-
Flag (bottom). (ii) htt1-588 (htt588; lane 1)
and htt588 S434A mutant (htt588 S434A;
lane 2) were pulled down, phosphorylated
(top), and blotted with anti-Flag (bottom) as
above. Note that only htt forms with S434
(lane 1) were efficiently phosphorylated. (B)
Htt551/empty vector (lane 1), htt551/p35
(lane 2 and 4), and htt551 S434A/p35 (lane
3) were cotransfected into cdk5-expressing
HeLa cells. After 24 h, cells were labeled with
[
32P]orthophosphate for 3 h, and one of the
htt551/p35 transfections (lane 4) was treated
with 20  M of the cdk5 inhibitor roscovitine
(Rosco) during this process. Htt551 was pulled
down with anti-Flag and subjected to SDS-
PAGE and transferred to PVDF membrane for
autoradiography (top) and immunoblotting
with anti-Flag. (C) An alignment of htt from mini-pig, human, mouse, rat, fugu, and zebrafish. The conserved phosphorylation-determining amino acid
residues are highlighted. (D) Purified GST or GST-htt588 were phosphorylated by p35–cdk5 complex in vitro as described in Materials and methods.
1/100 of the mixtures were subjected to SDS-PAGE and Western blot using phospho-htt antibody, pS434 (top), and anti-GST. (E) Htt551/empty vector
(lane 1), htt551/p35 (lane 2), htt551 S434A/empty vector (lane 3), and htt551 S434A/p35 (lane 4) were transfected into HeLa cells. After 24 h, cells
were harvested, lysates were subjected to SDS-PAGE, transferred to PVDF membrane, and then probed with anti-pS434 (top). The same membrane was
probed with anti-Flag (bottom) after stripping. (F) Htt551-138Q (muhtt) was cotransfected with empty vector (lane 1) or p35 (lane 2). After 24 h, cell
lysates were subjected to Western blot and probed with anti-pS434 (top) and anti-Flag (bottom). (G) 5  g of empty vector, cdk5, and cdk5DN were
cotransfected to PC-12 cells in 10-cm dishes with 1  g EGFP. The transfected cells were starved for 24 h and treated with NGF for 4 h. FACS was used to
sort GFP-positive (i.e., transfected) cells. Those GFP-positive cell lysates were subjected to Western blot probed with anti-pS434 (top) and anti-htt (bottom),
respectively. Newborn mouse brain lysate (lane 5) was probed with anti-pS434 (top) and anti-htt (bottom). 
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compared with empty vector transfected cells, and in the rosco-
vitine-treated cells, the phosphorylation is fully disabled (Fig. 4
G). These data also confirm that anti-pS434 can specifically
recognize cdk5-phosphorylated forms of full-length htt. Anti-
pS434 identified a band of the same mobility as the rosco-
vitine/cdk5DN-sensitive band seen in the PC-12 cells in new-
born mouse brain, suggesting that endogenous mouse htt is
phosphorylated at S434 (Fig. 4 G, lane 5).
 
Cdk5 phosphorylation of mutant htt 
reduces its toxicity
 
To investigate if cdk5 could modulate mutant htt toxicity,
we transfected httmu588 (httmu588 [138Q] with empty vec-
tor), httmu588/p35 (httmu588 with p35), httmu588 S434A
(httmu588 S434A with empty vector), or httmu588 S434A/p35
(httmu588 S434A with p35) into SK-N-SH (neuroblastoma)
cells, which express cdk5 but not the activators like p35/p39
(Fig. 5 A). Activation of endogenous cdk5 kinase activity in
these cells by p35 reduced the proportions of cells with aggre-
gates or cell death in the cells expressing httmu588 but did not
reduce either the proportions of cells with aggregates or cell
death in cells expressing httmu588 S434A, the nonphosphory-
latable httmu588 form (Fig. 5 A). Thus, activation (by p35) of
cdk5 activity is required in order for it to protect against the
toxicity of httmu588 in neuronal cells. Furthermore, this is not
a nonspecific protective effect of cdk5 activation but requires S
at residue 434 in httmu588.
 
Cdk5 phosphorylation of htt reduces its 
cleavage by caspases
 
We considered that p35–cdk5 may protect against httmu588
by modulating its turnover, but this hypothesis was not sup-
ported by our initial experiments (unpublished data). Because
cdk5 phosphorylation of httmu551 was associated with a re-
duction of its cleavage product htt 513 (Fig. 4 F), we tested if
p35–cdk5 phosphorylation modulated htt cleavage. Because
htt cleavage at sites close to S434 is mediated by caspases, we
established assays for htt cleavage in HeLa cells treated with
low doses of the caspase-inducing drug staurosporine. We
transfected p35 into HeLa cells to activate cdk5 kinase activ-
ity. Fig. 5 B shows that staurosporine treatment results in
cleavage of htt551 (e.g., Fig. 5 B, lanes 5 and 6). The cleavage
of htt551 (as judged by the ratio of htt551 to 513) in the cells
with p35 transfection (Fig. 5 B, lane 2) was obviously less
than that in cells without p35 transfection (Fig. 5 B, lane 6).
Also, p35 expression does not alter htt551 expression (unpub-
lished data). Although p35–cdk5 activity regulated htt551
cleavage induced by staurosporine, it did not reduce stauro-
sporine-induced cleavage of the htt551 S434A mutant (Fig. 5
B, lanes 4 and 8). Thus, htt551 cleavage is specifically regu-
lated by p35–cdk5 acting at S434. Some htt551 cleavage oc-
curred in the absence of staurosporine and p35 (Fig. 5 B). This
result may be due to low levels of active caspases (e.g., result-
ing from transfection), although we cannot exclude a role for
other proteases.
We tested if p35–cdk5 regulated cleavage of mutant htt.
Fig. 5 C shows that httmu551 cleavage (Fig. 5 C, lanes 1 and 2)
was consistently much less in p35-expressing cells, compared
with cells not transfected with p35 (Fig. 5 C, lanes 3 and 4) in
either staurosporine-treated or untreated conditions. Staurospo-
rine-induced htt551 cleavage in cell models is caspase-depen-
dent, as cleavage of htt551 was effectively prevented by the
pan-caspase inhibitor Z-VAD-fmk (unpublished data). Because
mutant htt cleavage enhances its aggregate formation and tox-
icity, these data can account for the protective effects observed
against httmu588 by p35–cdk5 (Fig. 5 A).
Figure 5. Cdk5-phosphorylating htt blocks caspase cleavage and regulates
mutant htt toxicity. (A) Httmu588/vector, httmu588/p35, httmu588
S434A/vector, and httmu588 S434A/p35 were transfected to cdk5-
expressing neuroblastoma SK-N-SH cells. After 48 h, cells were fixed and
immunostained with anti-Flag and p35 antibodies. Htt-expressing cells
were scored for the presence of aggregates and abnormal nuclei. Data
are from three independent experiments. Each experiment was performed
in triplicate. Error bars represent SD. ***, P   0.0001; **, P   0.001.
(B) p35 was cotransfected with htt551 (lanes 1 and 2) or htt551 S434A
(lanes 3 and 4), or empty vector was cotransfected with htt551 (lanes 5
and 6) or htt551 S434A (lanes 7 and 8) into HeLa cells. After 24 h, cells
were treated with 1 M staurosporine (STS) for 0 (lanes 1, 3, 5, and 7) or
6 h (lanes 2, 4, 6, and 8). Cell lysates were resolved with 10% SDS-PAGE
and transferred to PVDF membrane for Western blotting. The variation in
the amount of htt expressed in this transient transfection experiment can
vary from well to well depending on the transfection efficiency in the
specific well (as well as survival when treated with STS). We are primarily
concerned with the proportion of the protein that is cleaved. Quantitation
of the intact/cleaved(513) htt ratios from of the scanned original gel is
shown. The phenomena shown in this figure were reproduced in independent
experiments. (C) p35 was cotransfected with muhtt551 (lanes 1 and 2), or
empty vector was cotransfected with htt551 (lanes 3 and 4) into cdk5-
expressing HeLa cells. After 24 h, cells were treated with 1  M staurosporine
(STS) for 0 (lanes 1 and 3) or 6 h (lanes 2 and 4). Cell lysates were resolved
with 10% SDS-PAGE and transferred to PVDF membrane for Western blot.
(D) Htt551 and htt551 S434A were in vitro translated with 
35S-labeling.
The in vitro–translated htt551 (lane 3) and htt551 S434A (lane 6) were
phosphorylated in vitro in the presence of recombinant p35–cdk5 com-
plex and ATP- -S. The unphosphorylated (lane 2) and phosphorylated
htt551 (lane 3) and unphosphorylated (lane 5) and phosphorylated
htt551 S434A (lane 6) were subjected to caspase-3 cleavage (100 ng/ml).
10% SDS-PAGE was performed. Data show a representative of three inde-
pendent experiments. 
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Because Wellington et al. (1998, 2000) reported that htt
can be cleaved by caspase-3 at D513, we tested if cdk5 phos-
phorylation of htt changed its susceptibility to caspase-3 cleav-
age in vitro. In vitro–translated 
 
35
 
S-labeled htt551 was phos-
phorylated in vitro in the presence of recombinant p35–cdk5 and
ATP-
 
 
 
-S, which can phosphorylate htt551. The use of ATP-
 
 
 
-S
ensures stability of the phosphorylated site, as the resulting thio-
phosphorylation is resistant to phosphatase attack. Cdk5-phos-
phorylated htt551 (Fig. 5 D, lane 3) is cleaved less by caspase-3
compared with htt551 that has not been cdk5 phosphorylated
(Fig. 5 D, lane 2) or htt551 S434A with or without cdk5–p35
phosphorylation (showing the effect is dependent on the pres-
ence of htt S434; Fig. 5 D). Quantification of Fig. 5 D revealed
that cdk5 phosphorylation of htt551 increased the ratio of
htt551 to htt513 by 1.7-fold in the presence of caspase-3,
whereas there was no obvious effect of this phosphorylation in
the htt551 S434A mutant (under the same conditions). The
phosphorylation probably does not have a more pronounced ef-
fect in this experiment, as it is very likely that only a proportion
of the molecules are stably phosphorylated (and thus protected
from cleavage) under in vitro conditions. Thus, cdk5 phos-
phorylation of htt prevents its cleavage by caspases and can ac-
count for activated cdk5 inhibiting httmu588-induced cell death
and aggregation. Because htt phosphorylation by cdk5 pre-
vented its cleavage by caspases in vitro, it is likely that this ef-
fect is regulated by phosphorylation itself rather than by interac-
tion of other proteins at the phosphorylation site.
To confirm that cdk5 activity is an important regulator of
full-length htt cleavage in vivo, we studied neuronally differen-
tiated PC-12 cells (Sugars et al., 2004), which express either
NH
 
2
 
-terminal Flag-tagged wild-type or mutant, full-length htt
under the control of a doxycycline-responsive promoter (Tet-On).
We can detect NH
 
2
 
-terminal cleavage products of these trans-
genes specifically using an anti-Flag antibody in these cell
lines. The transgene expression levels in these cells is similar to
the endogenous htt (Sugars et al., 2004). We used these cells to
test our prediction that inhibition of cdk5 activity with its inhib-
itor roscovitine would result in more transgene cleavage at resi-
due 513. Compared with untreated cells, roscovitine-treated
NGF-differentiated cells produced more of the caspase cleav-
age fragment, htt513 (Fig. 6 A). The ratio of htt552 to htt 513
was dramatically reduced in the roscovitine-treated cells, which
is consistent with greater cleavage at amino acid 513 in the
absence of cdk5 activity. In stable inducible, neuronally dif-
ferentiated PC-12 cells expressing mutant 138Q full-length
transgenes, enhanced htt cleavage would be predicted to result
in more aggregates, as aggregation is enhanced by short NH
 
2
 
-
terminal htt products, compared with longer fragments. Consis-
tent with our previous data showing that cdk5-mediated phos-
phorylation reduces htt cleavage at D513, aggregate formation
was substantially increased in neuronally differentiated PC-12
cells treated with roscovitine while expressing the transgene,
compared with untreated cells (Fig. 6 B, i and ii). Compared
with untreated cells, roscovitine treatment of these cells pro-
duced more of the caspase-cleavage fragment htt513 (Fig. 6 B),
and the ratio of htt552 to htt 513 was dramatically reduced in the
roscovitine-treated cells, which is consistent with greater cleav-
age at amino acid 513 in the absence of cdk5 activity. Rosco-
vitine was not toxic to PC-12 cells under these conditions (un-
published data). We could not evaluate mutant htt-induced cell
death in this model as cell death rates are very low in this cell
model expressing mutant full-length htt (Sugars et al., 2004).
 
Cdk5 activity is reduced in HD 
transgenic mouse brains
 
Because cdk5 activity is protective against mutant htt cleavage
and toxicity, we investigated if this activity was altered in a
mouse model of HD expressing the first 171 residues of htt
with expanded polyQs (Schilling et al., 1999). Surprisingly, the
specific activity of cdk5 immunoprecipitated from brains of
mice carrying the mutant transgene was significantly lower
than that (of comparable amounts of cdk5) from wild-type lit-
termates (Fig. 7 A). However, p35 levels were not reduced in
brain lysates from the mutant HD mice (Fig. 7 B). Furthermore,
cdk5 and p35 were not sequestered into either cytosolic or nu-
clear htt aggregates in vivo. Samples from human HD brains
and HD transgenic mouse brains (and relevant non-HD con-
trols) were analyzed using both peroxidase and immunofluo-
rescence detection systems and no aggregates staining for ei-
ther cdk5 or p35 were seen, whereas convincing aggregate
staining was seen with both antiubiquitin and anti-htt antibod-
ies (unpublished data).
Figure 6. Inhibition of cdk5 activity promotes htt
cleavage, and mutant htt aggregate formation in
differentiated htt stable PC-12 cells. (A) Wild-type,
full-length htt PC-12 cells were differentiated with 100
ng/ml NGF for 48 h. 1   g/ml doxycycline was
added to induce htt expression for 5 d. At same time,
indicated samples in duplicate were also treated with
20  M of the cdk5 inhibitor roscovitine. Cells were
harvested and subjected to 7.5% SDS-PAGE. Anti-
Flag (M2) was used for Western blot. This antibody
detects a 3  Flag tag at the NH2-terminal of the htt
transgene. (B) Mutant full-length htt PC-12 cells were
differentiated with 100 ng/ml NGF for 48 h. 1  g/ml
doxycycline was added to induce htt expression for 5 d. At the same time as inducing transgene expression, cells were also treated with 20  M of the
cdk5 inhibitor roscovitine, where indicated. Cells were fixed and anti-Flag (M2) was used for immunocytochemistry. This antibody detects a 3  FLAG tag
at the NH2-terminal of the htt transgene. (i) The proportions of cells with aggregates are shown. Experiment was performed in triplicate. Error bars repre-
sent SD. *, P   0.01. (ii) Mutant, full-length htt PC-12 cells were differentiated with NGF, induced with doxycycline, and treated with roscovitine as
wild-type, full-length htt PC-12 cells. Cells were harvested and subjected to 10% SDS-PAGE. Anti-Flag (M2) was used for Western blot. This antibody detects
a 3  Flag tag at the NH2-terminal of the htt transgene. 
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Because htt interacts with cdk5, we hypothesized that the
polyQ expansion may reduce cdk5 activity by impairing its in-
teraction with p35. Fig. 7 C shows that much less p35 was
pulled down by anti-cdk5 from HD compared with wild-type
littermate brain lysate, although comparable amounts of cdk5
were pulled down in the two samples, supporting our hypothe-
sis that mutant htt impairs the p35–cdk5 interaction. Next, we
used GFP-htt exon1-23Q (GFP-httEx1-23Q) and GFP-htt
exon1-74Q (GFP-httEx1-74Q) in cellular models to confirm
the data from HD mice because htt exon1 is sufficient to bind
to cdk5. Fig. 7 D shows cdk5 pulled down significantly less
p35 in the presence of GFP-httEx1-74Q, compared with cdk5
in the presence of GFP-httEx1-23Q. However, comparable
amounts of p35 and cdk5 were seen in the total lysates, and
similar levels of cdk5 were immunoprecipitated in cells ex-
pressing 23Q or 74Q (Fig. 7 D, lanes 1 and 3). To confirm that
polyQ-expanded htt impeded the p35–cdk5 interaction, we
cotransfected p35–cdk5 and increasing amounts of httEx1-74Q
into COS-7 cells, and then anti-cdk5 was used to pull down p35
and httEx1-74Q in cell lysates (Fig. 7 E). The levels of p35 that
were pulled down by cdk5 decreased with the increasing ex-
pression of httEx1-74Q.
Next, we tested if endogenous htt phosphorylation was
affected in our HD mice that express the first 171 residues of
mutant htt because cdk5 activity is reduced in these mice (Fig.
7 A). Htt S434 phosphorylation (phospho-htt/total htt ratio)
was significantly reduced in 8- (presymptomatic) or 17-wk-old
(symptomatic) HD mouse brain lysates, compared with non-
transgenic age-matched littermates (Fig. 7 F; by 33% and 17%,
respectively). The apparent differences in the reduction in htt
phosphorylation at 8 and 17 wk may simply be because the ex-
periments at these time points were performed at different
times and on different blots.
 
Htt588 or full-length htt stabilizes p35–
cdk5 interaction and expanded polyQ of 
mutant htt decreases this stabilization
 
Because htt toxicity is believed to be exposed after cleavage,
we tested if mutant htt588 mutant full-length htt reduced
the  p35–cdk5 interaction. Surprisingly, we found that both
httwt588 and httmu588 (Fig. 8 A) and full-length wthtt and
muhtt (Fig. 8 B) increased the p35–cdk5 interaction. However,
mu588 and mutant full-length were less effective than their wt
counterparts (Fig. 8, A and B). However, exon1-23Q does
not  significantly alter the affinity of p35–cdk5 interaction,
whereas exon1-74Q interferes with the interaction, which is
consistent with Fig. 7 (C–E). The cleavage of full-length htt
and htt588 may explain why the mutant forms of these pro-
teins are less effective than their wild-type counterparts at sta-
bilizing the cdk5–p35 interaction because mutant htt exon 1
impairs p35–cdk5 binding. In addition, we consistently ob-
served that more mutant htt than wild-type protein was pulled
Figure 7. Mutant htt impairs cdk5 activity by
interfering p35–cdk5 interaction. (A) Cdk5
was pulled down from the lysates of wild-type
littermate control (Ctrl; lane 1) or HD (lane 2)
mice whole brains (12 wk). Histone H1 was
used as a substrate for kinase assays. Radio-
photographs and Western blots were quanti-
fied. Six independent experiments were per-
formed. Error bars represent SD. *, P   0.05.
Note that kinase activity is expressed as a
function of cdk5 levels (specific activity). (B)
Whole brain lysates of 13-wk wild-type litter-
mate control (Ctrl; lane 1) and HD (lane 2)
mice were subjected to SDS-PAGE, and West-
ern blots were probed successively with anti-
p35 (top), -cdk5 (middle), and -tubulin (bottom
panel) antibodies. (C) Anti-cdk5 (J3, monoclo-
nal) was used to pull down p35 from 13-wk-
old wild-type littermate control (lane 1) and
HD (lane 2) mouse whole brain lysates. Anti-
p35 (C-19, polyclonal) was used to detect
p35 (top). After stripping, the same mem-
brane was probed with anti-cdk5 (C8, poly-
clonal) to measure cdk5 levels (second panel).
P35 (third panel) and cdk5 (bottom) levels in
total control (lane 1) and HD (lane 2) mouse
brain lysates are shown. Data show a repre-
sentative experiment from three independent
experiments. (D) Anti-cdk5 (J3, monoclonal) was used to pull down p35 from p35/cdk5/GFP-httEx1-23Q- (1:1:2) (lane 1) and p35/cdk5/GFP-httEx1-
74Q- (1:1:2) (lane 3) transfected COS-7 cell lysates. Anti-p35 (C-19, polyclonal) was used to detect p35 (top). After stripping, the same membrane was
probed with anti-cdk5 (C8, polyclonal) to measure cdk5 levels (second panel). P35 (third) and cdk5 (bottom) levels in total p35/cdk5/GFP-httEx1-23Q-
(lane 1) and p35/cdk5/GFP-httEx1-74Q- (lane 3) transfected COS-7 cell lysates are shown. Data show a representative experiment from four independent
experiments. (E) p35–cdk5 (0.75  g each) were cotransfected with 0 (lane 1), 0.5 (lane 2), 1 (lane 3), 2 (lane 4), and 3  g httEx1-74Q (lane 5), respectively.
Note that the total amount of DNA transfected was kept constant by adding empty vector DNA, where necessary. After 48 h, anti-cdk5 was used to
immunoprecipitate p35 in each transfected cell. IP products (left) and total cell lysates (right) were detected with anti-GFP, anti-p35, and anti-cdk5, respectively.
(F, left) 8-wk-old HD (lane 2) and nontransgenic (lane 1) mouse whole brain lysates were subjected Western blot and probed with anti-pSer434 (top)
and anti-htt (bottom). One of the phtt/htt ratios was set as 1 and data were quantified. Error bars represent SD. *, P   0.05. (right) 17-wk-old HD (lanes
3 and 4) and nontransgenic (lanes 1 and 2) mouse whole brain lysates (40  g) were subjected to Western blot and probed with anti-pS434 (top) and
anti-htt (bottom). One of the phtt/htt ratios was set as 1. Western blot was quantified. Error bars represent SD. *, P   0.05. 
JCB • VOLUME 169 • NUMBER 4 • 2005 654
 
down using anti-cdk5 (J3) (Fig. 8), which we did not observe
using anti-Flag antibody. The stronger binding is not nonspe-
cific because neither httw588 nor httmu588 were pulled down
by anti-cdk5 in httwt588- or httmu588-only transfected cell ly-
sates. (Please note that it is almost impossible to achieve equal
transfection efficiencies of exon 1 htt, htt588, and full-length
htt in the same experiment due to the vastly different sizes of
the expression vectors.)
The data in cell and mouse models suggest that the inter-
action between cdk5 and its activator p35 is impaired by NH
 
2
 
-
terminal mutant htt, which accounts for the reduced cdk5 activ-
ity we observed in HD mouse brains. Thus, the ability of cdk5
to prevent htt cleavage by caspases may be partially abrogated
in HD mouse brains.
 
Discussion
 
Here, we show that htt selectively interacts with cdk5 but not
its activator, p35. Recent data showed that Akt and the serum-
and glucocorticoid-induced kinase SGK phosphorylate htt at
serine 421 and regulate its toxicity (Humbert et al., 2002;
Rangone et al., 2004), although the mechanisms remain un-
known. We show that htt is a cdk5 substrate at S434 and phos-
phorylation at this site reduces htt cleavage at D513, although
we cannot exclude other cdk5 phosphorylation sites beyond
htt588. The exact mechanism whereby phosphorylation leads
to decreased caspase cleavage is still not clear; however, a
likely explanation is that the negative charge (and possibly
altered structure) conferred by phosphorylation inhibits the
accessibility of caspases to their recognition site. Protein
phosphorylation regulating caspase-mediated cleavage hap-
pens in many proteins. Casein kinase I and II phosphorylation
of Bid regulates its cleavage by caspase-8 (Desagher et al.,
2001), ERK phosphorylation of caspase-9 regulates its pro-
cessing (Allan et al., 2003), and MAPK phosphorylation of
the androgen receptor enhances its cleavage by caspase-3
(LaFevre-Bernt and Ellerby, 2003).
Cdk5-mediated htt phosphorylation appears to be an im-
portant regulator of mutant htt cleavage, aggregation, and tox-
icity. Our data are consistent with those of Wellington et al.
(2000, 2002), who provided biochemical and in vivo data sup-
porting cleavage of mutant htt at caspase sites in HD. Htt phos-
phorylation at S434 provides a novel means of regulating an
early and likely rate-limiting event in HD pathogenesis. Al-
though our data implicate caspases as important and possibly
rate-limiting components of the htt cleavage cascade, it is im-
portant to consider this in the context of other proteases con-
tributing to the process, like calpains, aspartic proteases, and
possibly other as yet uncharacterized proteases.
Cdk5 activity and phosphorylation of endogenous htt at
S434 were reduced in htt 171 HD transgenic mice, and our data
suggest that this results from mutant htt reducing the associa-
tion between cdk5 and its activator p35. The interaction be-
tween p35 and cdk5 may be affected by the polyQ expansion in
mutant htt, which appears to interact more strongly with cdk5
compared with wild-type htt. These data predict that the ability
of cdk5 phosphorylation to protect against htt cleavage, aggre-
gation, and toxicity is compromised in cells expressing toxic
fragments of htt.
Our data raise the speculation that there may be a positive
feedback loop acting to enhance the progression of mutant htt
cytotoxicity in humans. The idea of a positive feedback loop is
supported by our observation that mutant exon1 fragments re-
duce cdk5–p35 interactions (compared with either wild-type
exon 1 or empty vector control), whereas longer products
(1–588 or full length) increase the stability of the p35–cdk5 in-
teraction compared with empty vector. This finding is seen
with both mutant and wild-type forms of htt 1–588 or the full-
length protein. It is interesting to contrast the cdk5 situation with
our previous observation of mutant htt interacting with the mTOR
kinase (Ravikumar et al., 2004). Although mutant htt results in
loss of function of both kinases, in the mTOR case, the interac-
tion is mainly due to a direct sequestration effect in aggregates
and leads to some effects that are protective. As discussed in
the previous paragraph, the inhibition of cdk5 activity is medi-
ated by soluble mutant htt and is likely to be deleterious. Nev-
ertheless, this raises the possibility that truncated forms of mu-
tant htt may bind preferentially to several kinases and cause
diverse physiological changes.
Figure 8. Htt588 or full-length htt stabilizes p35–cdk5 interaction, and
expanded polyQ of mutant htt compromises this stablization. (A) p35–cdk5
(0.75  g each) were cotransfected into HeLa cells with 1  g of empty
vector (lane 1), 0.5  g httwt588 ( 0.5  g of empty vector, to ensure
similar amounts of DNA transfected in all lanes) (lane 2), 1  g httwt588
(lane 3), 0.5  g httmu588 ( 0.5  g empty vector) (lane 4), and 1  g
httmu588 (lane 5). After 24 h, cell lysates were subjected to IP with mouse
anti-cdk5 (J3). The IP products were probed with anti-p35, anti-cdk5, and
anti-Flag (for htt), respectively. Data represent a representative of experi-
ments repeated four times with similar trends. (B) p35–cdk5 (0.75  g
each) were cotransfected with empty vector (lane 1), httwt588 (lane 2),
httmu588 (lane 3), wtFLhtt (lane 4), muwtFLhtt (lane 5), httEx1-23Q (lane
6), and httEx1-74Q (lane 7) into HeLa cells; the ratio of p35/cdk5/htt is
1:1:2. The cell lysates were immunoprecipitated with anti-cdk5. The IP
products were then probed with anti-p35, anti-cdk5, anti-Flag (for htt588
and full-length htt), and anti-GFP (for GFP-httEx1). Similar results were
observed in another two independent experiments. 
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Although the reduction of htt phosphorylation at the cdk5
site in HD mice brain may appear to be modest, this reflects the
average of a heterogenous population of neurons with different
susceptibilities to mutant htt toxicity and different stages of the
pathogenic process. Indeed, it is quite feasible that even a small
perturbation resulting in a positive feedback process would have
major consequences in the context of decades in human HD.
Once a certain level of cleavage has occurred, this would release
a toxic product that would inhibit cdk5 activity, which would in
turn enhance cleavage. A positive feedback loop is one type of
process that can account for the fact that most HD patients are
clinically unaffected and have normal brain morphology/vol-
ume until a decade or so before the disease manifests in middle
age and that the rate of neurodegeneration seems much faster af-
ter onset than before onset. Such a feedback loop would also be
accelerated in rare HD patients who have inherited two ex-
panded alleles (“homozygotes”) and may account for the obser-
vation that the progression of disease appears to be more rapid
in such cases, compared with heterozygotes who have similar
ages at onset (Squitieri et al., 2003). In addition to these direct
effects of cdk5 on htt, it is possible that reduced cdk5 activity
may also have other consequences for HD pathogenesis.
 
Materials and methods
 
Generation of anti–pSer434-htt antibody
 
In brief, the Ser434-phosphorylated peptide of htt, C-GGSSSpSPVLSR
(Sigma-Aldrich), was used to immunize two rabbits. Serum was collected
from the two rabbits after four injections. The serum was passed through
unphosphorylated peptide-conjugated Sepharose (Pierce Chemical Co.).
The flow-through was passed over phosphorylated peptide-conjugated
Sepharose. The phosphorylated antibody, designated as pS434, was
eluted with 0.1 M glycine, pH 2.3.
 
Immunoprecipitation (IP)
 
IP was performed using buffer A (20 mM Tris-HCl, pH 7.2, 2 mM MgCl
 
2
 
,
150 mM NaCl, 5 mM NaF, 1 mM Na
 
3
 
VO
 
4
 
, 0.5% NP-40, and protease
inhibitor cocktail [Roche]). Cells were lysed in buffer A for 20 min on ice,
followed by centrifugation at 13,000 
 
g
 
 for 15 min. Primary antibodies (or
anti-Flag M2-agarose affinity gel and anti-cdk5 (J3)–coupling gel [Pierce
Chemical Co.]) were added to a final concentration of 5
 
  
 
g/ml and incu-
bated for 2 h to overnight at 4
 
 
 
C. Anti–mouse or –rabbit IgG agarose
were added to the mixture and incubated at 4
 
 
 
C for 1 h. After three wash-
ings, IP products were either directly boiled in Laemmli buffer or eluted
with 0.1 M glycine, pH 2.3, and then boiled in Laemmli buffer and sub-
jected to PVDF membrane transfer and Western blot.
 
GST pull-down assay
 
GST or GST-htt (aa5-56) expressed in BL21 (DE3) were adsorbed to glu-
tathione-agarose beads for 1 h after 3
 
 
 
 PBS washing. The bound GST or
GST-htt (aa 5–56) were incubated with the lysate of COS-7 cells trans-
fected with cdk5 in buffer A for 2 h at 4
 
 
 
C, and then washed three times
in buffer A. The bound proteins were resolved by SDS-PAGE and trans-
ferred to PVDF membrane. The blot was probed with anti-cdk5.
 
LM and cytosol fractionation
 
Cells or mouse brains were suspended in STM buffer (10 mM KCl, 10 mM
Tris, pH 7.9, 1 mM DTT, 250 mM sucrose, and protease inhibitors cocktail)
at 4
 
 
 
C, incubated for 20 min on ice with swirling, and lysed by 20 strokes
in a Dounce homogenizer. The homogenate was clarified at 15,000 
 
g
 
 for
15 min at 4
 
 
 
C, and the supernatant was centrifuged for 1 h at 100,000 
 
g
 
at 4
 
 
 
C. The second supernatant and pellet were collected as cytosol and
LM, respectively. The LM include Golgi, endosomes, and all ER vesicles.
LM were lysed in buffer A.
 
Quantification of autoradiographs
 
To quantify cdk5 level in LM in the presence or absence of htt, the speci-
fied bands were analyzed by ChemiImager (Alpha Innotech Co.). Cdk5/
actin (for LM cdk5 level) of total lysates were set as 1, and the relative val-
ues of LM cdk5/actin was analyzed.
 
Cellular fragmentation of mouse brains
 
Mouse brains were suspended in buffer A, incubated for 20 min on ice
with swirling, and lysed by 20 strokes in a Dounce homogenizer. The ho-
mogenate was clarified at 15,000 
 
g
 
 for 10 min at 4
 
 
 
C, and the superna-
tant was collected for Western blot or IP.
 
In vitro kinase assay
 
Kinase assays were performed by washing immunoprecipitates twice with
buffer A and twice with kinase buffer (50 mM Hepes, pH 7.0, 10 mM
MgCl
 
2
 
, and 1 mM DTT). p35–cdk5 complexes were incubated with 50  l
of kinase buffer containing the substrate 5  Ci  -[
32P]ATP at RT for 30
min. After boiling, mixtures were separated by SDS-PAGE and transferred
to PVDF membrane.
Metabolic labeling
HeLa cells were transfected with htt551 for 24 h. The cells were incubated
with 0.3 mCi/ml [
32P]orthophosphate (Amersham Biosciences) in phos-
phate-free DME for 4 h at 37 C. The cells were lysed in 0.5 ml of buffer A.
Htt was immunoprecipitated using anti-Flag, separated by SDS-PAGE,
transferred to PVDF membrane, and analyzed by autoradiography. The
membrane was subsequently probed with anti-Flag.
Estimation of cell death and aggregates
To measure cell death or aggregates,  200 transfected cells (as judged
by anti-Flag immunocytochemistry) were counted in multiple random visual
fields per slide. All coverslips were scored with the observer blinded to the
identity of the slides. Cells were analyzed using a fluorescent microscope
(model Eclipse E600; Nikon). The figures show data from representative
experiments in triplicate. Cell death was monitored by scoring the trans-
fected cells with apoptotic nuclear morphology—fragmented or pyknotic
nuclei. Cells were counted as aggregate-positive if one or several aggre-
gates were visible within a cell. P-values were determined by uncondi-
tional logistical regression analysis by using the general loglinear option
of 9.1 software (SPSS).
In vitro translation and cleavage
In vitro translations were performed in TNT-coupled reticulocyte lysate sys-
tems following Promega’s instruction. 2  l of 
35S-labeled products were
phosphorylated in the presence of cdk5–p35 complex and ATP- -S (if nec-
essary) and cleaved by 100 ng/ml caspase-3 in cleavage buffer (50 Mm
Hepes, pH 7.2, 50 mM NaCl, 0.1% Chaps, 10 mM EDTA, 5% glycerol,
and 10 mM DTT) for 1 h at 37 C. The cleaved products were subjected to
10% SDS-PAGE. Films were exposed after gel drying. We divided the in
vitro translated htt into three identical aliquots. One aliquot was phosphor-
ylated as described in the previous section and one was mock-phosphory-
lated by leaving out the cdk5–p35. These aliquots were treated identically
with the relevant caspase and compared with the third aliquot that was not
treated with caspase (or phosphorylated), the control uncleaved protein.
Online supplemental material
Details of vector construction, antibodies and reagents, cell culture and
treatments, and immunocytochemistry and microscopy are available on-
line. Online supplemental material is available at http://www.jcb.org/
cgi/content/full/jcb.200412071/DC1.
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